ForSight VISION4 Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ForSight VISION4 Inc.
Ogranon will pay $25m upfront for worldwide commercialization rights to ebopiprant for acute preterm labor, which currently has no approved treatments in the US.
In this audio interview, Organon’s head for the Asia Pacific region talks to Scrip on the company’s ambitions in the women’s health segment and the outlook for its biosimilars and established brands portfolios.
The Jada system has received 510(k) clearance from the US FDA to treat postpartum hemorrhage and abnormal postpartum uterine bleeding.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Site Specific
- Drug Delivery
- Other Names / Subsidiaries
- ForSight Labs